Wujie Wang

Wujie Wang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2018 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
YWYongzheng Wang
Yongzheng Wang
BLBin Liu
Bin Liu
PCPikun Cao
Pikun Cao
WWWujie Wang
Wujie Wang
WWWei Wang
Wei Wang
YLYuliang Li
Yuliang Li
Background: The study was conducted to investigate the effectiveness and cost of computed tomography (CT)‐guided percutaneous microwave ablation (MWA) and thoracoscopic lobectomy for stage I non‐small cell lung cancer (NSCLC).Methods: We retrospectively analyzed the data of 46 and 85 patients with stage I NSCLC treated with CT‐guided percutaneous MWA or thoracoscopic lobectomy, respectively, at our center from July 2013 to June 2015. Overall survival (OS), disease‐free survival (DFS), local control rate, hospital stay, and cost were evaluated. Survival curves were constructed using the Kaplan–Meier method and compared using the log‐rank test.Results: The one and two‐year OS rates were 97.82% and 91.30% and 97.65% and 90.59% in the MWA and lobectomy groups, respectively. The one and two‐year DFS rates were 95.65% and 76.09% and 95.29% and 75.29%, respectively. No significant differences were observed in log‐rank analysis between the groups (P = 0.169). The hospital stays in the MWA and lobectomy groups were 6.62 ± 2.31 and 9.57 ± 3.19 days, respectively. The costs of MWA and lobectomy were US$3274.50 ± US$233.91 and US$4678.87 ± US$155.96, respectively. The differences were all significant (P = 0.003).Conclusion: MWA and thoracoscopic lobectomy for stage I NSCLC demonstrate similar one and two‐year OS and DFS, with no significant differences between the two groups. MWA involved a shorter hospital stay and lower cost, thus should be considered a better option for patients with severe cardiopulmonary comorbidity and patients unwilling to undergo surgery.

1 March 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
PLPei-Min Li
Pei-Min Li
YLYu-Liang Li
Yu-Liang Li
BLBin Liu
Bin Liu
WWWujie Wang
Wujie Wang
YWYong-Zheng Wang
Yong-Zheng Wang
ZLZheng Li
Zheng Li
Curcumin Inhibits MHCC97H Liver Cancer Cells by Activating ROS/TLR-4/Caspase Signaling Pathway Curcumin;liver cancer;reactive oxygen species;toll-like receptor 4;apoptosis; Curcumin can inhibit proliferation of liver cancer cells by inducing apoptosis, but the specific signaling pathways involved are not completely clear. Here, we report that curcumin inhibited proliferation of MHCC97H liver cancer cells by induction of apoptosis in a concentration dependent manner via stimulating intracellular reactive oxygen species (ROS) generation. Also, we showed that increased intracellular ROS formation activated the TLR-4/MyD-88 signaling pathway, resulting in activation of caspase-8 and caspase-3, which eventually led to apoptosis in MHCC97H cells. These results showed that as an prooxidant, curcumin exerts anti-cancer effects by inducing apoptosis via the TLR-4/MyD-88 signaling pathway.

23 May 2015 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
YLYuliang Li
Yuliang Li
YJYunming Jia
Yunming Jia
SLShengyong Li
Shengyong Li
WWWujie Wang
Wujie Wang
ZWZhenting Wang
Zhenting Wang
ZLZheng Li
Zheng Li

30 November 2011 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YLYuliang Li
Yuliang Li
JGJianli Geng
Jianli Geng
YWYongzheng Wang
Yongzheng Wang
QLQinghua Lu
Qinghua Lu
YDYimeng Du
Yimeng Du
ZLZheng Li
Zheng Li

16 February 2023 in European Journal of Radiology
Verified
Journal Article
Closed access
AHAiqiang Han
Aiqiang Han
KYKunning Yang
Kunning Yang
XZXiaofa Zhang
Xiaofa Zhang
JPJianliang Pan
Jianliang Pan
AHAiqiang Han
Aiqiang Han
WWWujie Wang
Wujie Wang

1 January 2020 in International Journal of Hyperthermia
Verified
Journal Article
Open access
YWYongzheng Wang
Yongzheng Wang
LZLili Zhang
Lili Zhang
YLYuliang Li
Yuliang Li
WWWujie Wang
Wujie Wang
Background: The aim of this study was to assess the feasibility, safety and efficacy of computed tomography (CT)-guided percutaneous microwave ablation with artificial ascites for problematic hepatocellular tumors. Methods: Forty-eight patients with 61 problematic hepatocellular carcinomas who underwent CT-guided percutaneous microwave ablation with artificial ascites were reviewed retrospectively. Lesions less than 5 mm away from the gastrointestinal system, diaphragm, pericardium or kidney were defined as problematic tumors with the potential risk of thermal damage. Microwave ablation was performed after artificial ascites was established between tumors and the adjacent high-risk organs. The technical effectiveness of microwave ablation, local tumor progression and complications was assessed. Results: Microwave ablation with artificial ascites was successfully performed in all 61 tumors. The technical effectiveness rate was 100% with contrast-enhanced CT performed immediately after the ablation procedure. Local tumor progression occurred in three (6%) of the 48 patients during the follow-up period (mean, 15 months; range, 6–24 months). No major complications related to the procedure occurred. Conclusion: CT-guided percutaneous microwave ablation with artificial ascites is a feasible, safe and effective choice for treating problematic hepatocellular tumors, avoiding potential thermal damage to the adjacent high-risk organs.